Proscar Articles
Forest in patent settlement with Glenmark; Watson generic Lysteda cleared; and Dr Reddy's debuts generic Propecia
3 January 2013
US FDA panel negative on extending GSK’s Avodart and Merck & Co’s Proscar use; Agency delays ezogabine
2 December 2010
GlaxoSmithKline to invest £500 million in UK after tax promise; faces questions on Avodart benefits
30 November 2010
Pfizer debuts generic drug portfolio in the UK
3 February 2010
New guidelines to help boost use of 5-ARIs
9 March 2009
FDA says TV ad for GSK
9 March 2009
US FTC closes, freezes assets of vast drug spam e-mail network
27 October 2008
Dr Reddy's fiscal 2nd-qtr profits fall 4.5%
5 November 2007
Actavis debuts generic finasteride in USA
28 May 2007
Final FDA appro for Mylan's finasteride
22 December 2006
Dr Reddy's fiscal 2nd-qtr income hits $61M
6 November 2006
Dr Reddy's settles patent row with GSK
23 October 2006
FDA appro for Teva's generic Proscar
26 June 2006
Poland and Russia boost Zentiva sales
15 August 2005
Zentiva's 2004 EPS rockets 84.9%
21 March 2005
Tentative US OK for IVAX' generic Proscar
17 January 2005
Eating veggies together better against cancer
9 August 2004
Patent expiries "will stall BPH drug sales during 2007-12"
29 September 2003
Stock Commentary - New York
30 June 2003
Merck & Co's Proscar cuts prostate cancer risk
30 June 2003
GSK launches Avodart in UK
3 March 2003
Effect of Merck & Co Banyu buy assessed
27 January 2003
Banyu says Proscar still on file in Japan
3 June 2002
Dermatological drugs to reach $10 billion 2006
20 May 2002
Drugs ordered on-line without prescription
20 May 2002
GSK's dutasteride for BPH cleared in USA
7 January 2002
GSK's dutasteride for BPH cleared in USA
28 December 2001
MSD China launches Propecia
9 November 2001
Tokyo pharma stock market week to May 14
15 May 2001
Stock Commentary - Tokyo
1 February 2001
Yamanouchi sales up on forecasts
13 November 2000
Five-year data with Merck's Propecia
11 October 2000
Update - Merck's Propecia not on NHS in UK
15 June 2000
Merck's Propecia not on NHS in UK
12 June 2000
Korea approves Merck's Propecia
27 April 2000
Mail pharmacy sues state Attorney General
14 February 2000
UK announces "public consultation" period for Merck's Propecia
13 January 2000
Banyu results strong despite Lipovas decline
24 November 1999
Stock Commentary Tokyo
11 November 1999
Stock Commentary Tokyo
4 November 1999
MSD gains approval for Propecia in UK
26 October 1999
Banyu forecasts strong profits for 2004
11 October 1999
US doctor charged over Internet Rxing offenses
13 July 1999
Stock Commentary New York
27 May 1999
US DTC Rx ad spend hit $1.3 billion in 1998
25 May 1999
Merck disappointment as highly-touted antidepressant stalls
26 January 1999
US 2nd-Qtr Rx DTC Spending Rises 25%
6 November 1998
Healthy Third-Quarter Growth For US Drug Majors
22 October 1998
B-MS Licenses Unilever Hair Research
8 October 1998
Pfizer's Zyrtec Tops DTC Ad Spending In May
16 September 1998
US Rx DTC Ad Spend Set To Beat $1 Billion Again
28 July 1998
US Drug Stocks Plummet After Merck Disappoints
23 July 1998
FDA And "Lack Of Fair Balance" In DTC Ads
27 May 1998
Merck & Co's Propecia "Not Effective In Women"
14 May 1998
Unapproved Drugs Imported Into Japan
8 May 1998
Merck In $60 Million DTC Ads For Propecia
30 April 1998
US Quarterly Financial Results Round-Up
23 April 1998
Analysts Forecast Bright Outlook For US Majors
8 April 1998
FDA Approval News In Brief
2 April 1998
Pfizer's Impotence Pill Wins FDA Clearance
31 March 1998
Long-Term Efficacy With Merck & Co's Proscar
5 March 1998
Stock Commentary New York
5 March 1998
Top Pharma & Biotech Stock Picks For 1998
4 February 1998
Impact Of Propecia On Merck & Co Assessed
28 January 1998
Propecia Approved In USA For Male Pattern Baldness
12 January 1998
Analysts Assess Outlook For US Drug Majors
8 January 1998
New Products In 1998; A Look Ahead
6 January 1998
...Merck Confident It Can Hold Growth Rates
9 December 1997
FDA C'tee Raises Concerns Over Merck's Propecia
19 November 1997
New Data With Merck's Propecia
19 June 1997
UK OHE Views P-Is, Economic Evaluation
16 June 1997
Merck & Co's Propecia Shows Promise In Hair Loss
26 March 1997
Continued Approval Of Blockbuster Products In '97?
23 December 1996
US Quarterly Results Show Improvements
4 November 1996
Terazosin Superior To Finasteride For BPH
2 September 1996
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
